ENTA ENANTA PHARMACEUTICALS INC

Nasdaq enanta.com


$ 11.04 $ 0.00 (0 %)    

Friday, 17-Oct-2025 09:31:00 EDT
QQQ $ 597.63 $ -0.37 (-0.06 %)
DIA $ 459.77 $ 0.37 (0.08 %)
SPY $ 659.22 $ -0.30 (-0.05 %)
TLT $ 91.23 $ -0.02 (-0.02 %)
GLD $ 395.45 $ -1.67 (-0.42 %)
$ 11.38
$ 11.84
$ 11.00 x 100
$ 11.45 x 200
-- - --
$ 4.09 - $ 15.34
378,942
na
243.28M
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-Q
4 11-27-2024 09-30-2024 10-K
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-08-2024 12-31-2023 10-Q
8 11-22-2023 09-30-2023 10-K
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-08-2023 12-31-2022 10-Q
12 11-23-2022 09-30-2022 10-K
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-10-2022 12-31-2021 10-Q
16 11-24-2021 09-30-2021 10-K
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 02-09-2021 12-31-2020 10-Q
20 11-25-2020 09-30-2020 10-K
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 02-10-2020 12-31-2019 10-Q
24 11-27-2019 09-30-2019 10-K
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 02-08-2019 12-31-2018 10-Q
28 11-29-2018 09-30-2018 10-K
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 02-09-2018 12-31-2017 10-Q
32 12-11-2017 09-30-2017 10-K
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 02-09-2017 12-31-2016 10-Q
36 12-09-2016 09-30-2016 10-K
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 02-09-2016 12-31-2015 10-Q
40 12-11-2015 09-30-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 enanta-pharmaceuticals-to-showcase-rsv-drug-data-at-idweek-2025-highlighting-two-oral-once-daily-treatments

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule ...

 jefferies-upgrades-enanta-pharma-to-buy-raises-price-target-to-20

Jefferies analyst Akash Tewari upgrades Enanta Pharma (NASDAQ:ENTA) from Hold to Buy and raises the price target from $14 to...

 enanta-pharma-commences-50m-public-offering-with-option-to-sell-additional-75m-in-common-stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs f...

 westpark-capital-maintains-buy-on-enanta-pharma-raises-price-target-to-28

WestPark Capital analyst Ed Arce maintains Enanta Pharma (NASDAQ:ENTA) with a Buy and raises the price target from $24 to $28.

Core News & Articles

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and...

 enantas-rsv-pill-shows-promise-in-cutting-recovery-time-for-high-risk-adults

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) on Monday released topline data from RSVHR Phase 2b study of zelicapavir in outpati...

Core News & Articles

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...

 enanta-pharma-reports-topline-data-from-rsvhr-phase-2b-study-to-evaluate-efficacy-and-safety-of-zelicapavir-in-outpatient-adults-with-acute-rsv-infection

6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease ...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

 enanta-pharma-to-share-topline-results-from-rsvhr-phase-2b-study-evaluating-zelicapavir-for-treatment-of-rsv-in-high-risk-adults-on-sept-29

Conference Call and Webcast to Discuss Data on Monday, September 29at 8:30 a.m.

 evercore-isi-group-maintains-outperform-on-enanta-pharma-lowers-price-target-to-12

Evercore ISI Group analyst Liisa Bayko maintains Enanta Pharma (NASDAQ:ENTA) with a Outperform and lowers the price target f...

 westpark-capital-initiates-coverage-on-enanta-pharma-with-buy-rating-announces-price-target-of-24

WestPark Capital analyst Ed Arce initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Buy rating and announces Price Tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION